CO5160320A1 - Metodos y composiciones para la prevencion de tolerancia a medicamentos das. - Google Patents

Metodos y composiciones para la prevencion de tolerancia a medicamentos das.

Info

Publication number
CO5160320A1
CO5160320A1 CO99068642A CO99068642A CO5160320A1 CO 5160320 A1 CO5160320 A1 CO 5160320A1 CO 99068642 A CO99068642 A CO 99068642A CO 99068642 A CO99068642 A CO 99068642A CO 5160320 A1 CO5160320 A1 CO 5160320A1
Authority
CO
Colombia
Prior art keywords
tolerance
das
medicines
prevention
compositions
Prior art date
Application number
CO99068642A
Other languages
English (en)
Inventor
Ahmed Tahir
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26803748&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5160320(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Publication of CO5160320A1 publication Critical patent/CO5160320A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un método para evitar tolerancia a un broncodilatador en una mamífero, que comprende la administración de cantidades terapéuticamente efectivas del broncodilatador y de un efector.2Un método de tratar asma y patologías relacionadas en un mamífero, que comprende la administración de cantidades terapéuticamente efectivas de un broncodilatador y de un efector.2Una composición para el tratamiento de asma y patologías relacionadas en un mamífero, que comprende cantidades terapéuticamente efectivas de un broncodilatador y de un efector.
CO99068642A 1998-10-30 1999-10-29 Metodos y composiciones para la prevencion de tolerancia a medicamentos das. CO5160320A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10650798P 1998-10-30 1998-10-30
US09/362,540 US6235725B1 (en) 1998-10-30 1999-07-28 Methods and compositions for the prevention of tolerance to medications

Publications (1)

Publication Number Publication Date
CO5160320A1 true CO5160320A1 (es) 2002-05-30

Family

ID=26803748

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99068642A CO5160320A1 (es) 1998-10-30 1999-10-29 Metodos y composiciones para la prevencion de tolerancia a medicamentos das.

Country Status (25)

Country Link
US (1) US6235725B1 (es)
EP (1) EP1124563B1 (es)
JP (1) JP4585121B2 (es)
CN (2) CN1329496A (es)
AR (2) AR023911A1 (es)
AT (1) ATE277621T1 (es)
AU (1) AU760119B2 (es)
BR (1) BR9915818A (es)
CA (1) CA2348926C (es)
CO (1) CO5160320A1 (es)
CY (1) CY1107493T1 (es)
CZ (1) CZ297914B6 (es)
DE (1) DE69920734T2 (es)
ES (1) ES2228173T3 (es)
HK (1) HK1041596A1 (es)
HU (1) HUP0302492A3 (es)
IL (2) IL142865A0 (es)
IS (1) IS2321B (es)
NO (1) NO333194B1 (es)
NZ (1) NZ511399A (es)
PL (1) PL195592B1 (es)
PT (1) PT1124563E (es)
SK (1) SK285150B6 (es)
TW (1) TW565451B (es)
WO (1) WO2000025723A2 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
MXPA02005666A (es) * 2000-10-12 2002-11-29 Boehringer Ingelheim Pharma Nuevos polvos para anhalacion que contienen tiotropio.
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030070679A1 (en) * 2001-06-01 2003-04-17 Boehringer Ingelheim Pharma Kg Capsules containing inhalable tiotropium
US20030140920A1 (en) * 2001-10-26 2003-07-31 Dey L.P. Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
JP2003221335A (ja) 2001-10-26 2003-08-05 Dey Lp 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US6702997B2 (en) 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
US20030203930A1 (en) * 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
DK1511466T4 (en) * 2002-02-18 2015-03-30 Ockham Biotech Ltd Use of glycosaminoglycans, such as, for example, heparin, for the treatment of respiratory disorders such as COPD
EP1549337B1 (en) * 2002-02-18 2014-08-13 Ockham Biotech Limited Combination of DNase I and glycosaminoglycans for use in extracellular DNA clearance
CA2516331C (en) * 2002-02-18 2013-04-23 University Of Southampton Combination therapy using glycosaminoglycans and therapeutic agents for the treatment of respiratory disorders
ATE385193T1 (de) 2002-03-20 2008-02-15 Mannkind Corp Inhalationsgerät
AU2003225182B2 (en) * 2002-04-25 2009-02-26 Momenta Pharmaceuticals, Inc. Methods and products for mucosal delivery
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US7763280B2 (en) * 2002-11-28 2010-07-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing powder formulation for inhalation
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
EP1625851A4 (en) * 2003-05-16 2007-12-26 Bbk Bio Corp PREPARATION FOR PREVENTING CONTACT OF PATHOGEN BROOMS WITH A LIVING ORGANISM
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20050043343A1 (en) * 2003-07-28 2005-02-24 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
CN101010305B (zh) 2004-08-20 2010-08-11 曼金德公司 二酮哌嗪合成的催化反应
DK1791542T3 (en) 2004-08-23 2015-06-15 Mannkind Corp Diketopiperazinsalte for pharmaceutical delivery
MX358592B (es) 2005-09-14 2018-08-27 Mannkind Corp Método para formulación de fármaco basado en el aumento de la afinidad de superficies de micropartículas cristalinas hacia agentes activos.
RU2403059C2 (ru) 2006-02-22 2010-11-10 Маннкайнд Корпорейшн Способ улучшения фармацевтических свойств микрочастиц, содержащих дикетопиперазин и активный агент
KR101548092B1 (ko) 2008-06-13 2015-08-27 맨카인드 코포레이션 건조 분말 흡입기 및 약물 투여 시스템
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
ES2421385T3 (es) 2008-06-20 2013-09-02 Mannkind Corp Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2676695A3 (en) 2009-03-11 2017-03-01 MannKind Corporation Apparatus, system and method for measuring resistance of an inhaler
WO2010144789A2 (en) 2009-06-12 2010-12-16 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
US20130090371A1 (en) * 2010-04-20 2013-04-11 President And Fellows Of Harvard College Methods and compositions for inhibition of beta2-adrenergic receptor degradation
CN102985125A (zh) 2010-06-21 2013-03-20 曼金德公司 干粉药物输送***和方法
JP6133270B2 (ja) 2011-04-01 2017-05-24 マンカインド コーポレイション 薬剤カートリッジのためのブリスター包装
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
JP6018640B2 (ja) 2011-10-24 2016-11-02 マンカインド コーポレイション 疼痛を緩和するのに有効な鎮痛組成物並びに当該組成物を含む乾燥粉末及び乾燥粉末薬剤輸送システム
RU2650035C2 (ru) 2012-07-12 2018-04-06 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
EP3587404B1 (en) 2013-03-15 2022-07-13 MannKind Corporation Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
MX2020009878A (es) 2013-07-18 2022-07-27 Mannkind Corp Composiciones farmaceuticas en polvo seco estables al calor y metodos.
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
CN104069497A (zh) * 2014-06-27 2014-10-01 东莞市凯法生物医药有限公司 一种降低药物耐受性的组合物、方法及其应用
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US20190070244A1 (en) * 2017-06-30 2019-03-07 The New Zealand Institute For Plant And Food Research Limited Boysenberry compositions and methods of preparation and use thereof
CA3070571A1 (en) 2017-08-08 2019-02-14 Odette M. Shaw Boysenberry, apple, and blackcurrant compositions and methods of preparation and use therefor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1195497B (it) 1983-03-08 1988-10-19 Opocrin Spa Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprieta' farmacologiche per degradazione chimica di eparina
US4906476A (en) 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US5032679A (en) 1988-12-15 1991-07-16 Glycomed, Inc. Heparin fragments as inhibitors of smooth muscle cell proliferation
US5380716A (en) 1988-12-15 1995-01-10 Glycomed, Inc. Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
US5192548A (en) 1990-04-30 1993-03-09 Riker Laboratoires, Inc. Device
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5714376A (en) 1991-10-23 1998-02-03 Massachusetts Institute Of Technology Heparinase gene from flavobacterium heparinum
US5736124A (en) 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
CA2125665C (en) 1991-12-12 2001-06-12 Rachel Ann Akehurst Medicaments
WO1993011773A1 (en) * 1991-12-18 1993-06-24 Aktiebolaget Astra New combination of formoterol and budesonide
US5690910A (en) * 1995-08-18 1997-11-25 Baker Norton Pharmaceuticals, Inc. Method for treating asthma

Also Published As

Publication number Publication date
CZ20011518A3 (cs) 2002-04-17
HUP0302492A3 (en) 2005-05-30
NO20012097D0 (no) 2001-04-27
CN1572303A (zh) 2005-02-02
CN100352448C (zh) 2007-12-05
CA2348926C (en) 2011-08-23
DE69920734D1 (de) 2004-11-04
EP1124563A4 (en) 2002-01-02
PL195592B1 (pl) 2007-10-31
BR9915818A (pt) 2002-06-18
IS2321B (is) 2007-12-15
NO333194B1 (no) 2013-04-02
CY1107493T1 (el) 2013-03-13
CA2348926A1 (en) 2000-05-11
AR023911A1 (es) 2002-09-04
PL364727A1 (en) 2004-12-13
IL142865A0 (en) 2002-03-10
SK5902001A3 (en) 2002-07-02
CZ297914B6 (cs) 2007-04-25
JP2002535245A (ja) 2002-10-22
SK285150B6 (sk) 2006-07-07
HK1041596A1 (zh) 2002-07-12
US6235725B1 (en) 2001-05-22
ES2228173T3 (es) 2005-04-01
NZ511399A (en) 2004-09-24
DE69920734T2 (de) 2005-10-06
AR082913A2 (es) 2013-01-16
IL142865A (en) 2006-07-05
TW565451B (en) 2003-12-11
EP1124563A2 (en) 2001-08-22
AU760119B2 (en) 2003-05-08
PT1124563E (pt) 2005-01-31
EP1124563B1 (en) 2004-09-29
HUP0302492A2 (hu) 2003-11-28
ATE277621T1 (de) 2004-10-15
WO2000025723A3 (en) 2000-07-27
CN1329496A (zh) 2002-01-02
JP4585121B2 (ja) 2010-11-24
NO20012097L (no) 2001-06-15
AU1205100A (en) 2000-05-22
WO2000025723A2 (en) 2000-05-11
IS5928A (is) 2001-04-27

Similar Documents

Publication Publication Date Title
CO5160320A1 (es) Metodos y composiciones para la prevencion de tolerancia a medicamentos das.
BR9812753A (pt) Combinação farmacêutica, uso da mesma, processo para tratamento de uma doença inflamatória, e, composição farmacêutica
AR012671A1 (es) Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos
YU48600A (sh) Celekoksibne smese
BR0111206A (pt) Derivados de arilmetilamina para uso como inibidores de triptase
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
EP1007556A4 (en) TROPONIN SUB-UNITS AND FRAGMENTS FOR USE AS INHIBITORS OF ANGIOGENESIS
BR0010209A (pt) Composições para o tratamento de desordens do esÈfago
BR0110420A (pt) Agonistas muscarìnicos
GB9807639D0 (en) Anti-inflammatory agents
AR016751A1 (es) Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo
DE69905368D1 (en) Oxydiertes thymosin beta 4
BR9811099A (pt) Inibidores de urocinase
GEP20002013B (en) Therapeutical Means
BR9402962A (pt) Forma de dosagem farmacêutica comprimida, obréia farmacêutica comprimida processo para a preparação das mesmas
BR0209922A (pt) Método para tratar uma condição médica que envolve a angiogênese em um paciente, para inibir a vascularização de células endoteliais, e para tratar câncer em um mamìfero
BR9807673A (pt) Processos para tratar asma alérgica e dermatite em um humano e composição farmacêutica.
BR9814923A (pt) Método para tratamento de doença de alzheimer
NZ505073A (en) Pharmaceutical compositions comprising micelles comprising lipophilic glucocorticosteroid and only one surfactant, useful for treating allergic, inflammatory and intestinal diseases
CO5160321A1 (es) Novedosas composiciones de tipranavir y ritonavir
BR0109672A (pt) Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente
AU4830097A (en) Use of an extract of Cimicifuga
BR0010546A (pt) Terapia antiinflamatória para infecção mediada inflamatória
ES2188995T3 (es) Uso de un inhibidor de la h+, k+-atpasa en el tratamiento de los polipos nasales.
CA2343116A1 (en) Methods and compositions for increasing intestinal absorption of fats